Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022
08 March 2022 - 12:00AM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or
"Company"), a clinical stage biotechnology company developing
cellular therapies for chronic aging-related and life-threatening
conditions, today announced that the Company will release its
fourth quarter and year-end 2021 financial results on Friday, March
11, 2022 before the open of U.S. financial markets. Management will
host a conference call to discuss the Company’s financial results
and provide a corporate update on the same day at 8:30 a.m. EST.
Dial-in NumberU.S. Dial-in Number:
844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations
Dial-in Number: 929-526-1599Conference ID: 770734
U.S. Replay Dial-in Number: 929-458-6194Canada Replay Dial-in
Number: 226-828-7578All Other Locations Dial-in Number:
44-204-525-0658Conference ID: 443753
An audio webcast of the call may also be
accessed from the ‘Investors’ page of the Longeveron website at
www.longeveron.com. A replay of the call will be available on the
Longeveron website shortly after completion of the call.
About Longeveron
Longeveron is a clinical stage biotechnology
company developing cellular therapies for specific aging-related
and life-threatening conditions. The Company’s lead investigational
product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”),
which is derived from culture-expanded medicinal signaling cells
(MSCs) that are sourced from bone marrow of young, healthy adult
donors. Longeveron believes that by using the same cells that
promote tissue repair, organ maintenance, and immune system
function, it can develop safe and effective therapies for some of
the most difficult disorders associated with the aging process and
other medical disorders. Longeveron is currently sponsoring Phase 1
and 2 clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization, and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
INVESTORS & MEDIA:
Investors:Brendan PayneStern
Investor RelationsTel: (212) 362-1200Email:
Brendan.payne@sternir.com
Media:Neil HareGVC Strategies
Tel: (202) 550-0297Email: neil@gvcstrategies.com
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jul 2023 to Jul 2024